Alexander Scheiter
Overview
Explore the profile of Alexander Scheiter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheiter A, Lu L, Gao L, Feng G
Annu Rev Cancer Biol
. 2025 Feb;
8(1):15-33.
PMID: 39959686
The non-receptor tyrosine phosphatase SHP2 has been at the center of cell signaling research for three decades. SHP2 is required to fully activate the RTK-RAS-ERK cascade, although the underlying mechanisms...
2.
Strantz C, Bohm D, Ganslandt T, Borries M, Metzger P, Pauli T, et al.
BMC Med Inform Decis Mak
. 2025 Jan;
25(1):29.
PMID: 39819625
Background: Molecular tumor boards (MTBs) play a pivotal role in personalized oncology, leveraging complex data sets to tailor therapy for cancer patients. The integration of digital support and visualization tools...
3.
van Keulen A, Buettner S, Olthof P, Klumpen H, Erdmann J, Izquierdo-Sanchez L, et al.
Ann Surg Oncol
. 2024 Jun;
31(10):6495-6503.
PMID: 38896226
Background: Resection of perihilar cholangiocarcinoma (pCCA) is a complex procedure with a high risk of postoperative mortality and early disease recurrence. The objective of this study was to compare patient...
4.
Krebs M, Haller F, Sporl S, Gerhard-Hartmann E, Utpatel K, Maurus K, et al.
Eur J Cancer
. 2024 Jun;
207:114144.
PMID: 38852290
Purpose: Providing patient access to precision oncology (PO) is a major challenge of clinical oncologists. Here, we provide an easily transferable model from strategic management science to assess the outreach...
5.
Klemm S, Evert K, Utpatel K, Muggli A, Simile M, Chen X, et al.
BMC Cancer
. 2023 Nov;
23(1):1086.
PMID: 37946160
Background: Upregulation of the mitogen-activated protein kinase (MAPK) cascade is common in hepatocellular carcinoma (HCC). Neuroblastoma RAS viral oncogene homolog (NRAS) is mutated in a small percentage of HCC and...
6.
Kaneko K, Liang Y, Liu Q, Zhang S, Scheiter A, Song D, et al.
Elife
. 2023 Oct;
12.
PMID: 37846866
CD133 (prominin 1) is widely viewed as a cancer stem cell marker in association with drug resistance and cancer recurrence. Herein, we report that with impaired RTK-Shp2-Ras-Erk signaling, heterogenous hepatocytes...
7.
Scheiter A, Hierl F, Luke F, Keil F, Heudobler D, Einhell S, et al.
Br J Cancer
. 2022 Dec;
128(6):1134-1147.
PMID: 36572733
Background: Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from...
8.
Hatzipanagiotou M, Huber D, Thede E, Scheiter A, Fernandez-Pacheco M, Hetterich M, et al.
Arch Gynecol Obstet
. 2022 Dec;
307(6):1949-1955.
PMID: 36503976
Purpose: As breast-conserving surgery (BCS) has become the standard for treatment of early breast cancer, the need for new technologies to improve intraoperative margin assessment has become clear. Close or...
9.
Luke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291825
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the...
10.
Teufel A, Meindl-Beinker N, Hosel P, Gerken M, Roig A, Ebert M, et al.
J Cancer Res Clin Oncol
. 2022 Sep;
149(8):4579-4590.
PMID: 36163558
Background: Small bowel adenocarcinoma (SBA) remains a rare malignancy accounting for less than 5% of all the gastrointestinal tract cancers. However, only limited data and expert guidelines are available for...